Thermo Fisher Scientific Inc (TMO) moved down by 3.53%. The Healthcare Services & Equipment sector is down by 1.53%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) down 2.04%; Hims & Hers Health Inc (HIMS) down 2.94%; Stryker Corp (SYK) down 2.14%.

Thermo Fisher Scientific (TMO) experienced a decline today, primarily influenced by the impending ex-dividend date and recent insider selling activity. Shares often adjust downwards on or just before the ex-dividend date, as new buyers will not qualify for the upcoming dividend payment. The company's ex-dividend date for its quarterly dividend of $0.47 per share is set for tomorrow, March 13, 2026. This forward-looking adjustment in share price is a common market dynamic.
Adding to the downward pressure, the firm's CEO, Marc N. Casper, engaged in selling activity, offloading a notable number of shares on March 11, 2026. While such sales can be for various reasons, including personal financial planning, they are often perceived by the market as a negative signal, contributing to investor caution and potentially influencing short-term share price movements.
These company-specific factors appear to be the dominant drivers behind today's significant intraday volatility. While recent Q4 and full-year 2025 earnings reported on January 29, 2026, were strong and exceeded analyst estimates, and analysts generally maintain a positive outlook with "Moderate Buy" or "Strong Buy" ratings, these earlier positive indicators likely have already been factored into the stock's valuation. Furthermore, a recent market assessment on March 11, 2026, indicated that the stock had already shown a several-day and monthly decline, suggesting a broader weakness in the period leading up to today's movement.
Technically, Thermo Fisher Scientific Inc (TMO) shows a MACD (12,26,9) value of [-17.13], indicating a neutral signal. The RSI at 33.03 suggests neutral condition and the Williams %R at -84.95 suggests oversold condition. Please monitor closely.
Thermo Fisher Scientific Inc (TMO) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $44.56B, ranking 2 in the industry. The net profit is $6.70B, ranking 1 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $662.47, a high of $750.00, and a low of $595.00.
Company Specific Risks: